Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 3474 · Cannabinoid Safety and Regulation Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 321 Definitions; generally

+127 −01 of 4 shown
More for 21 U.S.C. § 321
Read § 321Only this section
4 changes the bill asks for here, 1 carried out
  1. Not carried out:

    in paragraph (g)(1)(C), by striking (other than food) and inserting (other than food or cannabinoid products);

    The bill points to paragraph (g) of § 321, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (g) in /us/usc/t21/s321
  2. Not carried out:

    in paragraph (ff)(1), by striking (other than tobacco) and inserting (other than a tobacco product or a cannabinoid product);

    The bill points to paragraph (ff) of § 321, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (ff) in /us/usc/t21/s321
  3. Not carried out:

    in paragraph (rr)(4), by inserting cannabinoid product, after medical device; and

    The bill points to paragraph (rr) of § 321, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (rr) in /us/usc/t21/s321
  4. Carried out:

    by adding at the end the following:(tt) (1) (A) The term “cannabis” means— (i) all parts of the plant Cannabis sativa L., whether growing or not; (ii) the seeds of such plant; (iii) the resin extracted from any part of such plant; and (iv) every compound, manufacture, salt, derivative, mixture, or preparation of …

§ 321(ss)–(ww)

Start of § 321 to (ss) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(ss)(1)(1) (1)
an infant formula; oran infant formula; or
(ss)(2)(2) (2)
a medical food, as defined in section 360ee(b)(3) of this title.a medical food, as defined in section 360ee(b)(3) of this title.
(tt)(tt) [inserted: ]
(tt)(1)(1) [inserted: ]
(tt)(1)(A)(A) [inserted: ]
[inserted: The term “cannabis” means—]
(tt)(1)(A)(i)(i) [inserted: ]
[inserted: all parts of the plant Cannabis sativa L., whether growing or not;]
(tt)(1)(A)(ii)(ii) [inserted: ]
[inserted: the seeds of such plant;]
(tt)(1)(A)(iii)(iii) [inserted: ]
[inserted: the resin extracted from any part of such plant; and]
(tt)(1)(A)(iv)(iv) [inserted: ]
[inserted: every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, or other constituent element derived from such plant.]
(tt)(1)(B)(B) [inserted: ]
[inserted: The term “cannabis” does not include—]
(tt)(1)(B)(i)(i) [inserted: ]
[inserted: any cannabis plant actively under cultivation that is being cultivated in accordance with the requirements of subtitle G of the Agricultural Marketing Act of 1946;]
(tt)(1)(B)(ii)(ii) [inserted: ]
[inserted: a cannabinoid product; or]
(tt)(1)(B)(iii)(iii) [inserted: ]
[inserted: the mature stalks of the plant Cannabis sativa L., fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted therefrom), fiber, oil, cake, or the sterilized seed of such plant that is incapable of germination.]
(tt)(2)(2) [inserted: ]
[inserted: The term “cannabinoid” means any of the following:]
(tt)(2)(A)(A) [inserted: ]
[inserted: Any chemical in any plant of the genus Cannabis that is unique in nature to such plant, including any of the following chemicals:]
(tt)(2)(A)(i)(i) [inserted: ]
[inserted: Tetrahydrocannabinol.]
(tt)(2)(A)(ii)(ii) [inserted: ]
[inserted: Cannabinol.]
(tt)(2)(A)(iii)(iii) [inserted: ]
[inserted: Cannabidiol.]
(tt)(2)(A)(iv)(iv) [inserted: ]
[inserted: Cannabigerol.]
(tt)(2)(A)(v)(v) [inserted: ]
[inserted: Cannabichromene.]
(tt)(2)(A)(vi)(vi) [inserted: ]
[inserted: Tetrahydrocannabivarin.]
(tt)(2)(A)(vii)(vii) [inserted: ]
[inserted: Cannabivarin.]
(tt)(2)(A)(viii)(viii) [inserted: ]
[inserted: Cannabidivarin.]
(tt)(2)(A)(ix)(ix) [inserted: ]
[inserted: Cannabielsion.]
(tt)(2)(A)(x)(x) [inserted: ]
[inserted: Cannabicyclol.]
(tt)(2)(A)(xi)(xi) [inserted: ]
[inserted: Cannabitriol.]
(tt)(2)(A)(xii)(xii) [inserted: ]
[inserted: Cannabicitran.]
(tt)(2)(B)(B) [inserted: ]
[inserted: Any isomer of a chemical described in clause (A), and any acids, acetates, salts, esters, ethers, and derivatives thereof.]
(tt)(2)(C)(C) [inserted: ]
[inserted: Any chemical, regardless of origin or method of production, that is equivalent in chemical structure to a chemical referred to in clause (A), or has both a similar terpenophenolic chemical structure and pharmacological effect to a chemical referred to in clause (A).]
(tt)(2)(D)(D) [inserted: ]
[inserted: Any chemical derived from a plant of the genus Cannabis that is a CB–1 or CB–2 receptor agonist or partial agonist.]
(tt)(2)(E)(E) [inserted: ]
[inserted: Any chemical that the Secretary has, by order, deemed to be a cannabinoid.]
(tt)(3)(3) [inserted: ]
(tt)(3)(A)(A) [inserted: ]
[inserted: The term “cannabinoid product” means any article or product, including its components or parts, that—]
(tt)(3)(A)(i)(i) [inserted: ]
[inserted: contains or purports to contain any quantity of 1 or more cannabinoids that are derived from hemp (as defined in section 297A of the Agricultural Marketing Act of 1946); and]
(tt)(3)(A)(ii)(ii) [inserted: ]
[inserted: is intended for use in, through any route of administration, or to be applied to, the body of humans or other animals.]
(tt)(3)(B)(B) [inserted: ]
[inserted: The term “cannabinoid product” does not include—]
(tt)(3)(B)(i)(i) [inserted: ]
[inserted: a drug that is subject to the requirements of chapter V or section 351 of the Public Health Service Act;]
(tt)(3)(B)(ii)(ii) [inserted: ]
[inserted: a device that is subject to the requirements of chapter V;]
(tt)(3)(B)(iii)(iii) [inserted: ]
[inserted: any cannabis plant actively under cultivation that is being cultivated in accordance with the requirements of subtitle G of the Agricultural Marketing Act of 1946; or]
(tt)(3)(B)(iv)(iv) [inserted: ]
[inserted: a virus, serum, toxin, or analogous product subject to the requirements of the eighth paragraph of the matter under the heading “BUREAU OF ANIMAL INDUSTRY” in the Act of March 4, 1913 (commonly known as the “Virus-Serum-Toxin Act”).]
(tt)(4)(4) [inserted: ]
[inserted: With respect to cannabis or a cannabinoid product, the term “manufacture” does not include the planting, cultivation, growing, or harvesting of cannabis.]
(tt)(5)(5) [inserted: ]
[inserted: With respect to a cannabinoid product, the term “serious adverse effect” means that use of the product—]
(tt)(5)(A)(A) [inserted: ]
[inserted: results in—]
(tt)(5)(A)(i)(i) [inserted: ]
[inserted: death;]
(tt)(5)(A)(ii)(ii) [inserted: ]
[inserted: a life-threatening adverse experience;]
(tt)(5)(A)(iii)(iii) [inserted: ]
[inserted: inpatient hospitalization or prolongation of existing hospitalization;]
(tt)(5)(A)(iv)(iv) [inserted: ]
[inserted: a persistent or significant disability or incapacity;]
(tt)(5)(A)(v)(v) [inserted: ]
[inserted: a congenital anomaly or birth defect; or]
(tt)(5)(A)(vi)(vi) [inserted: ]
[inserted: other serious medical event; or]
(tt)(5)(B)(B) [inserted: ]
[inserted: requires, based on reasonable medical judgment, a medical or surgical intervention to prevent an outcome described in clause (A).]
(uu)(uu) [inserted: ]
[inserted: The term “intended for human consumption”, with respect to a cannabinoid product, means a cannabinoid product intended for ingestion or inhalation by a human.]
(vv)(vv) [inserted: ]
[inserted: The term “tetrahydrocannabinol” means—]
(vv)(1)(1) [inserted: ]
[inserted: the chemical substance found in the Cannabis sativa L. plant, including the delta-6a, delta-7, delta-8, delta-9, delta-10a, and delta-10 forms, whether naturally occurring in the Cannabis sativa L. plant or synthetically or semi-synthetically derived;]
(vv)(2)(2) [inserted: ]
[inserted: all isomers of tetrahydrocannabinol, and any acids, acetates, metabolites (including 11-hydroxy-THC, 3-hydroxy-THC, and 7-hydroxy-THC and their isomers), salts, esters, ethers, and derivatives thereof, including its precursor form, tetrahydrocannabinolic acid;]
(vv)(3)(3) [inserted: ]
[inserted: tetrahydrocannabivarins, including delta-8 tetrahydrocannabivarin, and exo-tetrahydrocannabinol;]
(vv)(4)(4) [inserted: ]
[inserted: hydrogenated forms of tetrahydrocannabinol including hexahydrocannabinol, hexahydrocannabiphorol, and hexahydrocannabihexol;]
(vv)(5)(5) [inserted: ]
[inserted: analogues of tetrahydrocannabinols with an alkyl chain of four or more carbon atoms, including tetrahydrocannabiphorols, tetrahydrocannabiocytls, tetrahydrocannabihexols, or tetrahydrocannabutols; and]
(vv)(6)(6) [inserted: ]
[inserted: any combination of the chemical substances described in subparagraphs (1) through (5) whether naturally or artificially derived or synthetically or semi-synthetically produced.]
(ww)(ww) [inserted: ]
(ww)(1)(1) [inserted: ]
[inserted: The term “artificially or synthetically derived cannabinoid” means a cannabinoid or a cannabinoid-like compound that is produced using chemical synthesis, chemical modification, or chemical conversion, including by using in-vitro biosynthesis or other bioconversion.]
(ww)(2)(2) [inserted: ]
[inserted: The term “artificially or synthetically derived cannabinoid” does not include—]
(ww)(2)(A)(A) [inserted: ]
[inserted: a cannabinoid or a cannabinoid-like compound produced through the decarboxylation of naturally occurring cannabinoids from their acidic forms;]
(ww)(2)(B)(B) [inserted: ]
[inserted: a cannabinoid product or input that undergoes the removal of solvents, catalysts, or other unwanted materials from the cannabinoid product or input; or]
(ww)(2)(C)(C) [inserted: ]
[inserted: a semi-synthetic cannabinoid.]
(ww)(3)(3) [inserted: ]
(ww)(3)(A)(A) [inserted: ]
[inserted: For purposes of subparagraph (2)(C), the term “semi-synthetic cannabinoid” means a substance that is created by a single chemical reaction that converts one cannabinoid extracted from a cannabis plant directly into a different cannabinoid that is found in more than trace amounts in a cannabis plant.]
(ww)(3)(B)(B) [inserted: ]
[inserted: For purposes of subparagraph (2)(C), the term “semi-synthetic cannabinoid” includes a cannabinoid that is produced by the conversion of cannabidiol, including cannabinol and delta-8 tetrahydrocannabinol.]
(ww)(3)(C)(C) [inserted: ]
[inserted: For purposes of subparagraph (2)(C), the term “semi-synthetic cannabinoid” does not include a cannabinoid that is produced through the decarboxylation of naturally occurring acidic forms of cannabinoids into the corresponding neutral cannabinoid through the use of heat or light, without the use of chemical reagents or catalysts, and that results in no other chemical change.]

21 U.S.C. § 331 Prohibited acts

+31 −01 of 9 shown
More for 21 U.S.C. § 331
Read § 331Only this section
9 changes the bill asks for here, 1 carried out
  1. Not carried out:

    by inserting cannabinoid product, after tobacco product, each place it appears in paragraphs (g) and (h);

    The bill points to paragraph (g) of § 331, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (g) in /us/usc/t21/s331
  2. Not carried out:

    by inserting cannabinoid product, after tobacco product, each place it appears in paragraphs (g) and (h);

    The bill points to paragraph (h) of § 331, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (h) in /us/usc/t21/s331
  3. Not carried out:

    in paragraph (j), by striking or 920(b) and inserting 920(b), or 1103;

    The bill points to paragraph (j) of § 331, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (j) in /us/usc/t21/s331
  4. Not carried out:

    by striking 510 or 905 and inserting 510, 905, or 1103;

    The bill points to paragraph (p) of § 331, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (p) in /us/usc/t21/s331
  5. Not carried out:

    by striking or 905(j) and inserting 905(j), or 1103(g); and

    The bill points to paragraph (p) of § 331, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (p) in /us/usc/t21/s331
  6. Not carried out:

    by striking or 905(i)(3) and inserting , 905(i)(3), or 1103(g)(2);

    The bill points to paragraph (p) of § 331, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (p) in /us/usc/t21/s331
  7. Not carried out:

    in paragraph (q)(2) by inserting , cannabinoid product, after device;

    The bill points to paragraph (q) of § 331, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (q) in /us/usc/t21/s331
  8. Not carried out:

    in paragraph (r), by inserting cannabinoid product, after device, each place it appears; and

    The bill points to paragraph (r) of § 331, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (r) in /us/usc/t21/s331
  9. Carried out:

    by adding at the end the following:(jjj) (1) The sale or distribution of a cannabinoid product intended for human consumption and that contains detectable levels of any tetrahydrocannabinol to any person younger than 21 years of age. (2) The sale or distribution of an article that is a cannabinoid product and …

§ 331(hhh)–(lll)

Start of § 331 to (ggg)(2) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(hhh)(hhh) (hhh)
The failure to register or submit listing information in accordance with section 364c of this title.The failure to register or submit listing information in accordance with section 364c of this title.
(iii)(iii) (iii)
The refusal or failure to follow an order under section 364g of this title.The refusal or failure to follow an order under section 364g of this title.
(jjj)(jjj) [inserted: ]
(jjj)(1)(1) [inserted: ]
[inserted: The sale or distribution of a cannabinoid product intended for human consumption and that contains detectable levels of any tetrahydrocannabinol to any person younger than 21 years of age.]
(jjj)(2)(2) [inserted: ]
[inserted: The sale or distribution of an article that is a cannabinoid product and that contains alcohol, tobacco, nicotine, or another substance with effects that could interact with cannabinoids or enhance or alter the effects of cannabinoids, as determined by the Secretary through rulemaking.]
(jjj)(3)(3) [inserted: ]
[inserted: The failure of a manufacturer or distributor to notify the Attorney General of its knowledge of cannabinoid products used in illicit trade.]
(kkk)(kkk) [inserted: ]
(kkk)(1)(1) [inserted: ]
[inserted: The introduction or delivery for introduction into commerce of any cannabinoid product that is adulterated or misbranded.]
(kkk)(2)(2) [inserted: ]
[inserted: The introduction or delivery for introduction into interstate commerce of an article intended for ingestion in tablet, capsule, powder, softgel, gelcap, liquid, or other form, which is not represented as a conventional food and not represented for use as a sole item of a meal or of the diet if it—]
(kkk)(2)(A)(A) [inserted: ]
[inserted: contains any synthetic ingredient with a molecular structure that does not occur in nature; and]
(kkk)(2)(B)(B) [inserted: ]
[inserted: does not meet the definition of a dietary supplement in section 201(ff), except that this subsection does not apply to any article introduced or delivered for introduction into interstate commerce in compliance with chapter V, VI, or IX or with section 351 of the Public Health Service Act.]
(kkk)(3)(3) [inserted: ]
[inserted: The adulteration or misbranding of any cannabinoid product in commerce.]
(kkk)(4)(4) [inserted: ]
[inserted: The receipt in commerce of any cannabinoid product that is adulterated or misbranded, and the delivery or proffered delivery thereof for pay or otherwise.]
(kkk)(5)(5) [inserted: ]
[inserted: The alteration, mutilation, destruction, obliteration, or removal of the whole or any part of the labeling of, or the doing of any other act with respect to a cannabinoid product, if such act is done while such article is held for sale (whether or not the first sale) after shipment in commerce and results in such article being adulterated or misbranded.]
(lll)(lll) [inserted: ]
(lll)(1)(1) [inserted: ]
[inserted: The sale or distribution of a cannabinoid product intended for human consumption that contains multiple servings, unless the contents of such cannabinoid product are readily divisible into portions equivalent to one serving.]
(lll)(2)(2) [inserted: ]
[inserted: The sale or distribution of a cannabinoid product intended for human consumption that is in liquid form, unless such cannabinoid product—]
(lll)(2)(A)(A) [inserted: ]
[inserted: contains not more than one serving; or]
(lll)(2)(B)(B) [inserted: ]
[inserted: if the serving size is less than 1 fluid ounce, includes a convenient device for measuring servings, such as a dropper or measuring cup, unless it is a food.]

21 U.S.C. § 333 Penalties

+19 −5Shown
More for 21 U.S.C. § 333
Read § 333Only this section
8 changes the bill asks for here, 8 carried out
  1. Carried out:

    in the first sentence, by striking or (9) and inserting (9), or (11); and

  2. Carried out:

    by inserting or no-cannabinoid-product-sale order after no-tobacco-sale order each place it appears;

  3. Carried out:

    by inserting or no-cannabinoid-product-sale order after no-tobacco-sale order each place it appears; and

  4. Carried out:

    in the second sentence, by inserting or cannabinoid products, as applicable, after tobacco products;

  5. Carried out:

    in subparagraph (C), in the first sentence, by striking or (9) and inserting (9), or (11); and

  6. Carried out:

    in subparagraph (D) by inserting or no-cannabinoid-product-sale order after no-tobacco-sale order;

  7. Carried out:

    in paragraph (6), by inserting or no-cannabinoid- product-sale order after no-tobacco-sale order each place it appears; and

  8. Carried out:

    by adding at the end the following:(10) Civil monetary penalties for violation of cannabinoid product requirements.— (A) In general.— Any person who violates a requirement of this Act that relates to cannabinoid products shall be liable to the United States for a civil penalty in an amount not to exceed $15,000 …

§ 333(f)Violations related to devices(4)–(7)

Start of § 333 to (f)(4)(A)(ii) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(4)(B)(B) (B)
In determining the amount of a civil penalty under subparagraph (A)(ii), the Secretary shall take into consideration whether the responsible person is making efforts toward correcting the violation of the requirement of section 355(o), 355(p), or 355–1 of this title for which the responsible person is subject to such civil penalty.In determining the amount of a civil penalty under subparagraph (A)(ii), the Secretary shall take into consideration whether the responsible person is making efforts toward correcting the violation of the requirement of section 355(o), 355(p), or 355–1 of this title for which the responsible person is subject to such civil penalty.
(5)(5) (5)
(5)(A)(A) (A)
A civil penalty under paragraph (1), (2), (3), (4), or ([struck: 9]) shall be assessed, or a no-tobacco-sale order may be imposed, by the Secretary by an order made on the record after opportunity for a hearing provided in accordance with this subparagraph and section 554 of title 5. Before issuing such an order, the Secretary shall give written notice to the person to be assessed a civil penalty, or upon whom a no-tobacco-sale order is to be imposed, under such order of the Secretary’s proposal to issue such order and provide such person an opportunity for a hearing on the order. In the course of any investigation, the Secretary may issue subpoenas requiring the attendance and testimony of witnesses and the production of evidence that relates to the matter under investigation.A civil penalty under paragraph (1), (2), (3), (4), [inserted: (9), ]or ([inserted: 11]) shall be assessed, or a no-tobacco-sale order [inserted: or no-cannabinoid-product-sale order ]may be imposed, by the Secretary by an order made on the record after opportunity for a hearing provided in accordance with this subparagraph and section 554 of title 5. Before issuing such an order, the Secretary shall give written notice to the person to be assessed a civil penalty, or upon whom a no-tobacco-sale order [inserted: or no-cannabinoid-product-sale order ]is to be imposed, under such order of the Secretary’s proposal to issue such order and provide such person an opportunity for a hearing on the order. In the course of any investigation, the Secretary may issue subpoenas requiring the attendance and testimony of witnesses and the production of evidence that relates to the matter under investigation.
(5)(B)(B) (B)
In determining the amount of a civil penalty, or the period to be covered by a no-tobacco-sale order, the Secretary shall take into account the nature, circumstances, extent, and gravity of the violation or violations and, with respect to the violator, ability to pay, effect on ability to continue to do business, any history of prior such violations, the degree of culpability, and such other matters as justice may require. A no-tobacco-sale order permanently prohibiting an individual retail outlet from selling tobacco products shall include provisions that allow the outlet, after a specified period of time, to request that the Secretary compromise, modify, or terminate the order.In determining the amount of a civil penalty, or the period to be covered by a no-tobacco-sale order[inserted: or no-cannabinoid-product-sale order], the Secretary shall take into account the nature, circumstances, extent, and gravity of the violation or violations and, with respect to the violator, ability to pay, effect on ability to continue to do business, any history of prior such violations, the degree of culpability, and such other matters as justice may require. A no-tobacco-sale order [inserted: or no-cannabinoid-product-sale order ]permanently prohibiting an individual retail outlet from selling tobacco products [inserted: or cannabinoid products, as applicable, ]shall include provisions that allow the outlet, after a specified period of time, to request that the Secretary compromise, modify, or terminate the order.
(5)(C)(C) (C)
The Secretary may compromise, modify, or remit, with or without conditions, any civil penalty which may be assessed under paragraph (1), (2), (3), (4), or ([struck: 9]). The amount of such penalty, when finally determined, or the amount agreed upon in compromise, may be deducted from any sums owing by the United States to the person charged.The Secretary may compromise, modify, or remit, with or without conditions, any civil penalty which may be assessed under paragraph (1), (2), (3), (4), [inserted: (9), ]or ([inserted: 11]). The amount of such penalty, when finally determined, or the amount agreed upon in compromise, may be deducted from any sums owing by the United States to the person charged.
(5)(D)(D) (D)
The Secretary may compromise, modify, or terminate, with or without conditions, any no-tobacco-sale order.The Secretary may compromise, modify, or terminate, with or without conditions, any no-tobacco-sale order[inserted: or no-cannabinoid-product-sale order].
(6)(6) (6)
Any person who requested, in accordance with paragraph (5)(A), a hearing respecting the assessment of a civil penalty or the imposition of a no-tobacco-sale order and who is aggrieved by an order assessing a civil penalty or the imposition of a no-tobacco-sale order may file a petition for judicial review of such order with the United States Court of Appeals for the District of Columbia Circuit or for any other circuit in which such person resides or transacts business. Such a petition may only be filed within the 60-day period beginning on the date the order making such assessment was issued, or on which the no-tobacco-sale order was imposed, as the case may be.Any person who requested, in accordance with paragraph (5)(A), a hearing respecting the assessment of a civil penalty or the imposition of a no-tobacco-sale order [inserted: or no-cannabinoid- product-sale order ]and who is aggrieved by an order assessing a civil penalty or the imposition of a no-tobacco-sale order [inserted: or no-cannabinoid- product-sale order ]may file a petition for judicial review of such order with the United States Court of Appeals for the District of Columbia Circuit or for any other circuit in which such person resides or transacts business. Such a petition may only be filed within the 60-day period beginning on the date the order making such assessment was issued, or on which the no-tobacco-sale order [inserted: or no-cannabinoid- product-sale order ]was imposed, as the case may be.
(7)(7) (7)
If any person fails to pay an assessment of a civil penalty—If any person fails to pay an assessment of a civil penalty—
(7)(A)(A) (A)
after the order making the assessment becomes final, and if such person does not file a petition for judicial review of the order in accordance with paragraph (6), orafter the order making the assessment becomes final, and if such person does not file a petition for judicial review of the order in accordance with paragraph (6), or

§ 333(f)–(g)

(f)(7)(B)–(9)(B) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(f)(9)(B)(ii)(II)(II) (II)
in the case of a violation that continues after the Secretary provides written notice to such person, $250,000 for the first 30-day period (or any portion thereof) that the person continues to be in violation, and such amount shall double for every 30-day period thereafter that the violation continues, not to exceed $1,000,000 for any 30-day period, and not to exceed $10,000,000 for all such violations adjudicated in a single proceeding.in the case of a violation that continues after the Secretary provides written notice to such person, $250,000 for the first 30-day period (or any portion thereof) that the person continues to be in violation, and such amount shall double for every 30-day period thereafter that the violation continues, not to exceed $1,000,000 for any 30-day period, and not to exceed $10,000,000 for all such violations adjudicated in a single proceeding.
(f)(9)(B)(iii)(iii) (iii)
In determining the amount of a civil penalty under clause (i)(II) or (ii)(II), the Secretary shall take into consideration whether the person is making efforts toward correcting the violation of the requirements of the section for which such person is subject to such civil penalty.In determining the amount of a civil penalty under clause (i)(II) or (ii)(II), the Secretary shall take into consideration whether the person is making efforts toward correcting the violation of the requirements of the section for which such person is subject to such civil penalty.
(f)(10)(10) [inserted: Civil monetary penalties for violation of cannabinoid product requirements.—]
(f)(10)(A)(A) [inserted: In general.—]
[inserted: Any person who violates a requirement of this Act that relates to cannabinoid products shall be liable to the United States for a civil penalty in an amount not to exceed $15,000 for each such violation, and not to exceed $15,000,000 for all such violations adjudicated in a single proceeding.]
(f)(10)(B)(B) [inserted: Enhanced civil penalties.—]
[inserted: Any person who knowingly violates a requirement of this Act that relates to cannabinoid products shall be subject to a civil monetary penalty of—]
(f)(10)(B)(i)(i) [inserted: ]
[inserted: not to exceed $250,000 per violation, and not to exceed $10,000,000 for all such violations adjudicated in a single proceeding; or]
(f)(10)(B)(ii)(ii) [inserted: ]
[inserted: in the case of a violation that continues after the Secretary provides written notice of the violation to such person, $250,000 for the first 30-day period (or any portion thereof) that the person continues to be in violation, and such amount shall double for every 30-day period thereafter that the violation continues, not to exceed $10,000,000 for any 30-day period, and not to exceed $20,000,000 for all such violations adjudicated in a single proceeding.]
(f)(11)(11) [inserted: Repeated violations relating to cannabinoid products.—]
(f)(11)(A)(A) [inserted: In general.—]
[inserted: If the Secretary finds that a person has committed repeated violations of a requirement of this Act that relates to cannabinoid products at a particular retail or online outlet, or association of retail or online outlets, then the Secretary may impose a no-cannabinoid-product-sale order on that person prohibiting the sale of cannabinoid products in that outlet. A no-cannabinoid-product-sale order may be imposed with a civil penalty under paragraph (1).]
(f)(11)(B)(B) [inserted: Hearing.—]
[inserted: Prior to the entry of a no-cannabinoid-product-sale order under this paragraph, a person shall be entitled to a hearing pursuant to the procedures established through regulations of the Food and Drug Administration for assessing civil money penalties, including, at a retailer’s request, a hearing by telephone, or at the nearest regional or field office of the Food and Drug Administration, or at a Federal, State, or county facility within 100 miles from the location of the retail outlet, if such a facility is available.]
(g)(g) Violations regarding direct-to-consumer advertising(g) Violations regarding direct-to-consumer advertising
(g)(1)(1) (1)
With respect to a person who is a holder of an approved application under section 355 of this title for a drug subject to section 353(b) of this title or under section 262 of title 42, any such person who disseminates or causes another party to disseminate a direct-to-consumer advertisement that is false or misleading shall be liable to the United States for a civil penalty in an amount not to exceed $250,000 for the first such violation in any 3-year period, and not to exceed $500,000 for each subsequent violation in any 3-year period. No other civil monetary penalties in this chapter (including the civil penalty in subsection (f)(4)) shall apply to a violation regarding direct-to-consumer advertising. For purposes of this paragraph: (A) Repeated dissemination of the same or similar advertisement prior to the receipt of the written notice referred to in paragraph (2) for such advertisements shall be considered one violation. (B) On and after the date of the receipt of such a notice, all violations under this paragraph occurring in a single day shall be considered one violation. With respect to advertisements that appear in magazines or other publications that are published less frequently than daily, each issue date (whether weekly or monthly) shall be treated as a single day for the purpose of calculating the number of violations under this paragraph.With respect to a person who is a holder of an approved application under section 355 of this title for a drug subject to section 353(b) of this title or under section 262 of title 42, any such person who disseminates or causes another party to disseminate a direct-to-consumer advertisement that is false or misleading shall be liable to the United States for a civil penalty in an amount not to exceed $250,000 for the first such violation in any 3-year period, and not to exceed $500,000 for each subsequent violation in any 3-year period. No other civil monetary penalties in this chapter (including the civil penalty in subsection (f)(4)) shall apply to a violation regarding direct-to-consumer advertising. For purposes of this paragraph: (A) Repeated dissemination of the same or similar advertisement prior to the receipt of the written notice referred to in paragraph (2) for such advertisements shall be considered one violation. (B) On and after the date of the receipt of such a notice, all violations under this paragraph occurring in a single day shall be considered one violation. With respect to advertisements that appear in magazines or other publications that are published less frequently than daily, each issue date (whether weekly or monthly) shall be treated as a single day for the purpose of calculating the number of violations under this paragraph.

Rest of § 333 unchanged

21 U.S.C. § 334 Seizure

+5 −5Shown
More for 21 U.S.C. § 334
Read § 334Only this section
6 changes the bill asks for here, 6 carried out
  1. Carried out:

    in paragraph (1), by inserting cannabinoid product, after drug,; and

  2. Carried out:

    by striking and (H) Any punch and inserting (H) Any punch; and

  3. Carried out:

    by inserting before the period at the end the following: , and (I) Any adulterated or misbranded cannabinoid product;

  4. Carried out:

    in subsection (d)(1), by inserting cannabinoid product, after tobacco product,; and

  5. Carried out:

    in subsection (g), by striking or tobacco product each place it appears in paragraphs (1) and (2)(A) and inserting , tobacco product, or cannabinoid product.

  6. Carried out:

    in subsection (g), by striking or tobacco product each place it appears in paragraphs (1) and (2)(A) and inserting , tobacco product, or cannabinoid product.

§ 334(a)

WhereMarkThe Code nowMarkAs the bill would leave it
§ 334. Seizure§ 334. Seizure
(a)(a) Grounds and jurisdiction(a) Grounds and jurisdiction
(a)(1)(1) (1)
Any article of food, drug, or cosmetic that is adulterated or misbranded when introduced into or while in interstate commerce or while held for sale (whether or not the first sale) after shipment in interstate commerce, or which may not, under the provisions of section 331(ll), 344, or 355 of this title, be introduced into interstate commerce, shall be liable to be proceeded against while in interstate commerce, or at any time thereafter, on libel of information and condemned in any district court of the United States or United States court of a Territory within the jurisdiction of which the article is found. No libel for condemnation shall be instituted under this chapter, for any alleged misbranding if there is pending in any court a libel for condemnation proceeding under this chapter based upon the same alleged misbranding, and not more than one such proceeding shall be instituted if no such proceeding is so pending, except that such limitations shall not apply (A) when such misbranding has been the basis of a prior judgment in favor of the United States, in a criminal, injunction, or libel for condemnation proceeding under this chapter, or (B) when the Secretary has probable cause to believe from facts found, without hearing, by him or any officer or employee of the Department that the misbranded article is dangerous to health, or that the labeling of the misbranded article is fraudulent, or would be in a material respect misleading to the injury or damage of the purchaser or consumer. In any case where the number of libel for condemnation proceedings is limited as above provided the proceeding pending or instituted shall, on application of the claimant, seasonably made, be removed for trial to any district agreed upon by stipulation between the parties, or, in case of failure to so stipulate within a reasonable time, the claimant may apply to the court of the district in which the seizure has been made, and such court (after giving the United States attorney for such district reasonable notice and opportunity to be heard) shall by order, unless good cause to the contrary is shown, specify a district of reasonable proximity to the claimant’s principal place of business, to which the case shall be removed for trial.Any article of food, drug, [inserted: cannabinoid product, ]or cosmetic that is adulterated or misbranded when introduced into or while in interstate commerce or while held for sale (whether or not the first sale) after shipment in interstate commerce, or which may not, under the provisions of section 331(ll), 344, or 355 of this title, be introduced into interstate commerce, shall be liable to be proceeded against while in interstate commerce, or at any time thereafter, on libel of information and condemned in any district court of the United States or United States court of a Territory within the jurisdiction of which the article is found. No libel for condemnation shall be instituted under this chapter, for any alleged misbranding if there is pending in any court a libel for condemnation proceeding under this chapter based upon the same alleged misbranding, and not more than one such proceeding shall be instituted if no such proceeding is so pending, except that such limitations shall not apply (A) when such misbranding has been the basis of a prior judgment in favor of the United States, in a criminal, injunction, or libel for condemnation proceeding under this chapter, or (B) when the Secretary has probable cause to believe from facts found, without hearing, by him or any officer or employee of the Department that the misbranded article is dangerous to health, or that the labeling of the misbranded article is fraudulent, or would be in a material respect misleading to the injury or damage of the purchaser or consumer. In any case where the number of libel for condemnation proceedings is limited as above provided the proceeding pending or instituted shall, on application of the claimant, seasonably made, be removed for trial to any district agreed upon by stipulation between the parties, or, in case of failure to so stipulate within a reasonable time, the claimant may apply to the court of the district in which the seizure has been made, and such court (after giving the United States attorney for such district reasonable notice and opportunity to be heard) shall by order, unless good cause to the contrary is shown, specify a district of reasonable proximity to the claimant’s principal place of business, to which the case shall be removed for trial.
(a)(2)(2) (2)
The following shall be liable to be proceeded against at any time on libel of information and condemned in any district court of the United States or United States court of a Territory within the jurisdiction of which they are found: (A) Any drug that is a counterfeit drug, (B) Any container of a counterfeit drug, (C) Any punch, die, plate, stone, labeling, container, or other thing used or designed for use in making a counterfeit drug or drugs, (D) Any adulterated or misbranded device, (E) Any adulterated or misbranded tobacco product, (F) Any device that is a counterfeit device, (G) Any container, packaging, or labeling of a counterfeit device, [struck: and ](H) Any punch, die, plate, stone, labeling, container, or other thing used or designed for use in making a counterfeit device or devices.The following shall be liable to be proceeded against at any time on libel of information and condemned in any district court of the United States or United States court of a Territory within the jurisdiction of which they are found: (A) Any drug that is a counterfeit drug, (B) Any container of a counterfeit drug, (C) Any punch, die, plate, stone, labeling, container, or other thing used or designed for use in making a counterfeit drug or drugs, (D) Any adulterated or misbranded device, (E) Any adulterated or misbranded tobacco product, (F) Any device that is a counterfeit device, (G) Any container, packaging, or labeling of a counterfeit device, (H) Any punch, die, plate, stone, labeling, container, or other thing used or designed for use in making a counterfeit device or devices[inserted: , and (I) Any adulterated or misbranded cannabinoid product].
(a)(3)(3) (3)
(a)(3)(A)(A) (A)
Except as provided in subparagraph (B), no libel for condemnation may be instituted under paragraph (1) or (2) against any food which—Except as provided in subparagraph (B), no libel for condemnation may be instituted under paragraph (1) or (2) against any food which—

§ 334(c)–(d)

(a)(3)(A)(i)–(b) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(c)(c) Availability of samples of seized goods prior to trial(c) Availability of samples of seized goods prior to trial
The court at any time after seizure up to a reasonable time before trial shall by order allow any party to a condemnation proceeding, his attorney or agent, to obtain a representative sample of the article seized and a true copy of the analysis, if any, on which the proceeding is based and the identifying marks or numbers, if any, of the packages from which the samples analyzed were obtained.The court at any time after seizure up to a reasonable time before trial shall by order allow any party to a condemnation proceeding, his attorney or agent, to obtain a representative sample of the article seized and a true copy of the analysis, if any, on which the proceeding is based and the identifying marks or numbers, if any, of the packages from which the samples analyzed were obtained.
(d)(d) Disposition of goods after decree of condemnation; claims for remission or mitigation of forfeitures(d) Disposition of goods after decree of condemnation; claims for remission or mitigation of forfeitures
(d)(1)(1) (1)
Any food, drug, device, tobacco product, or cosmetic condemned under this section shall, after entry of the decree, be disposed of by destruction or sale as the court may, in accordance with the provisions of this section, direct and the proceeds thereof, if sold, less the legal costs and charges, shall be paid into the Treasury of the United States; but such article shall not be sold under such decree contrary to the provisions of this chapter or the laws of the jurisdiction in which sold. After entry of the decree and upon the payment of the costs of such proceedings and the execution of a good and sufficient bond conditioned that such article shall not be sold or disposed of contrary to the provisions of this chapter or the laws of any State or Territory in which sold, the court may by order direct that such article be delivered to the owner thereof to be destroyed or brought into compliance with the provisions of this chapter, under the supervision of an officer or employee duly designated by the Secretary, and the expenses of such supervision shall be paid by the person obtaining release of the article under bond. If the article was imported into the United States and the person seeking its release establishes (A) that the adulteration, misbranding, or violation did not occur after the article was imported, and (B) that he had no cause for believing that it was adulterated, misbranded, or in violation before it was released from customs custody, the court may permit the article to be delivered to the owner for exportation in lieu of destruction upon a showing by the owner that all of the conditions of section 381(e) of this title can and will be met. The provisions of this sentence shall not apply where condemnation is based upon violation of section 342(a)(1), (2), or (6), section 351(a)(3), section 352(j), or section 361(a) or (d) of this title. Where such exportation is made to the original foreign supplier, then subparagraphs (A) and (B) of section 381(e)(1) of this title and the preceding sentence shall not be applicable; and in all cases of exportation the bond shall be conditioned that the article shall not be sold or disposed of until the applicable conditions of section 381(e) of this title have been met. Any person seeking to export an imported article pursuant to any of the provisions of this subsection shall establish that the article was intended for export at the time the article entered commerce. Any article condemned by reason of its being an article which may not, under section 344 or 355 of this title, be introduced into interstate commerce, shall be disposed of by destruction.Any food, drug, device, tobacco product, [inserted: cannabinoid product, ]or cosmetic condemned under this section shall, after entry of the decree, be disposed of by destruction or sale as the court may, in accordance with the provisions of this section, direct and the proceeds thereof, if sold, less the legal costs and charges, shall be paid into the Treasury of the United States; but such article shall not be sold under such decree contrary to the provisions of this chapter or the laws of the jurisdiction in which sold. After entry of the decree and upon the payment of the costs of such proceedings and the execution of a good and sufficient bond conditioned that such article shall not be sold or disposed of contrary to the provisions of this chapter or the laws of any State or Territory in which sold, the court may by order direct that such article be delivered to the owner thereof to be destroyed or brought into compliance with the provisions of this chapter, under the supervision of an officer or employee duly designated by the Secretary, and the expenses of such supervision shall be paid by the person obtaining release of the article under bond. If the article was imported into the United States and the person seeking its release establishes (A) that the adulteration, misbranding, or violation did not occur after the article was imported, and (B) that he had no cause for believing that it was adulterated, misbranded, or in violation before it was released from customs custody, the court may permit the article to be delivered to the owner for exportation in lieu of destruction upon a showing by the owner that all of the conditions of section 381(e) of this title can and will be met. The provisions of this sentence shall not apply where condemnation is based upon violation of section 342(a)(1), (2), or (6), section 351(a)(3), section 352(j), or section 361(a) or (d) of this title. Where such exportation is made to the original foreign supplier, then subparagraphs (A) and (B) of section 381(e)(1) of this title and the preceding sentence shall not be applicable; and in all cases of exportation the bond shall be conditioned that the article shall not be sold or disposed of until the applicable conditions of section 381(e) of this title have been met. Any person seeking to export an imported article pursuant to any of the provisions of this subsection shall establish that the article was intended for export at the time the article entered commerce. Any article condemned by reason of its being an article which may not, under section 344 or 355 of this title, be introduced into interstate commerce, shall be disposed of by destruction.
(d)(2)(2) (2)
The provisions of paragraph (1) of this subsection shall, to the extent deemed appropriate by the court, apply to any equipment or other thing which is not otherwise within the scope of such paragraph and which is referred to in paragraph (2) of subsection (a).The provisions of paragraph (1) of this subsection shall, to the extent deemed appropriate by the court, apply to any equipment or other thing which is not otherwise within the scope of such paragraph and which is referred to in paragraph (2) of subsection (a).
(d)(3)(3) (3)
Whenever in any proceeding under this section, involving paragraph (2) of subsection (a), the condemnation of any equipment or thing (other than a drug) is decreed, the court shall allow the claim of any claimant, to the extent of such claimant’s interest, for remission or mitigation of such forfeiture if such claimant proves to the satisfaction of the court (i) that he has not committed or caused to be committed any prohibited act referred to in such paragraph (2) and has no interest in any drug referred to therein, (ii) that he has an interest in such equipment or other thing as owner or lienor or otherwise, acquired by him in good faith, and (iii) that he at no time had any knowledge or reason to believe that such equipment or other thing was being or would be used in, or to facilitate, the violation of laws of the United States relating to counterfeit drugs.Whenever in any proceeding under this section, involving paragraph (2) of subsection (a), the condemnation of any equipment or thing (other than a drug) is decreed, the court shall allow the claim of any claimant, to the extent of such claimant’s interest, for remission or mitigation of such forfeiture if such claimant proves to the satisfaction of the court (i) that he has not committed or caused to be committed any prohibited act referred to in such paragraph (2) and has no interest in any drug referred to therein, (ii) that he has an interest in such equipment or other thing as owner or lienor or otherwise, acquired by him in good faith, and (iii) that he at no time had any knowledge or reason to believe that such equipment or other thing was being or would be used in, or to facilitate, the violation of laws of the United States relating to counterfeit drugs.

§ 334(f)–(g)

(e)–(f) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(f)(2)(2) (2)
The court to which such case was removed shall have the powers and be subject to the duties, for purposes of such case, which the court from which removal was made would have had, or to which such court would have been subject, if such case had not been removed.The court to which such case was removed shall have the powers and be subject to the duties, for purposes of such case, which the court from which removal was made would have had, or to which such court would have been subject, if such case had not been removed.
(g)(g) Administrative restraint; detention orders(g) Administrative restraint; detention orders
(g)(1)(1) (1)
If during an inspection conducted under section 374 of this title of a facility or a vehicle, a device, drug, [struck: or] tobacco product which the officer or employee making the inspection has reason to believe is adulterated or misbranded is found in such facility or vehicle, such officer or employee may order the device, drug, [struck: or] tobacco product detained (in accordance with regulations prescribed by the Secretary) for a reasonable period which may not exceed twenty days unless the Secretary determines that a period of detention greater than twenty days is required to institute an action under subsection (a) or section 332 of this title, in which case he may authorize a detention period of not to exceed thirty days. Regulations of the Secretary prescribed under this paragraph shall require that before a device, drug, [struck: or] tobacco product may be ordered detained under this paragraph the Secretary or an officer or employee designated by the Secretary approve such order. A detention order under this paragraph may require the labeling or marking of a device, drug, [struck: or] tobacco product during the period of its detention for the purpose of identifying the device, drug, [struck: or] tobacco product as detained. Any person who would be entitled to claim a device, drug, [struck: or] tobacco product if it were seized under subsection (a) may appeal to the Secretary a detention of such device, drug, [struck: or] tobacco product under this paragraph. Within five days of the date an appeal of a detention is filed with the Secretary, the Secretary shall after affording opportunity for an informal hearing by order confirm the detention or revoke it.If during an inspection conducted under section 374 of this title of a facility or a vehicle, a device, drug, [inserted: ,] tobacco product[inserted: ,] [inserted: or cannabinoid product ]which the officer or employee making the inspection has reason to believe is adulterated or misbranded is found in such facility or vehicle, such officer or employee may order the device, drug, [inserted: ,] tobacco product[inserted: ,] [inserted: or cannabinoid product ]detained (in accordance with regulations prescribed by the Secretary) for a reasonable period which may not exceed twenty days unless the Secretary determines that a period of detention greater than twenty days is required to institute an action under subsection (a) or section 332 of this title, in which case he may authorize a detention period of not to exceed thirty days. Regulations of the Secretary prescribed under this paragraph shall require that before a device, drug, [inserted: ,] tobacco product[inserted: ,] [inserted: or cannabinoid product ]may be ordered detained under this paragraph the Secretary or an officer or employee designated by the Secretary approve such order. A detention order under this paragraph may require the labeling or marking of a device, drug, [inserted: ,] tobacco product[inserted: ,] [inserted: or cannabinoid product ]during the period of its detention for the purpose of identifying the device, drug, [inserted: ,] tobacco product[inserted: ,] [inserted: or cannabinoid product ]as detained. Any person who would be entitled to claim a device, drug, [inserted: ,] tobacco product[inserted: ,] [inserted: or cannabinoid product ]if it were seized under subsection (a) may appeal to the Secretary a detention of such device, drug, [inserted: ,] tobacco product[inserted: ,] [inserted: or cannabinoid product ]under this paragraph. Within five days of the date an appeal of a detention is filed with the Secretary, the Secretary shall after affording opportunity for an informal hearing by order confirm the detention or revoke it.
(g)(2)(2) (2)
(g)(2)(A)(A) (A)
Except as authorized by subparagraph (B), a device, drug, [struck: or] tobacco product subject to a detention order issued under paragraph (1) shall not be moved by any person from the place at which it is ordered detained until—Except as authorized by subparagraph (B), a device, drug, [inserted: ,] tobacco product[inserted: ,] [inserted: or cannabinoid product ]subject to a detention order issued under paragraph (1) shall not be moved by any person from the place at which it is ordered detained until—
(g)(2)(A)(i)(i) (i)
released by the Secretary, orreleased by the Secretary, or
(g)(2)(A)(ii)(ii) (ii)
the expiration of the detention period applicable to such order,the expiration of the detention period applicable to such order,

Rest of § 334 unchanged

21 U.S.C. § 374 Inspection

+2 −2Shown
More for 21 U.S.C. § 374
Read § 374Only this section
4 changes the bill asks for here, 4 carried out
  1. Carried out:

    by inserting cannabinoid products, after tobacco products, each place it appears;

  2. Carried out:

    by striking or tobacco products each place it appears and inserting tobacco products, or cannabinoid products; and

  3. Carried out:

    by striking and tobacco products and inserting tobacco products, and cannabinoid products; and

  4. Carried out:

    in subsection (b)(1), by inserting cannabinoid product, after tobacco product,.

§ 374(a)

WhereMarkThe Code nowMarkAs the bill would leave it
§ 374. Inspection§ 374. Inspection
(a)(a) Right of agents to enter; scope of inspection; notice; promptness; exclusions(a) Right of agents to enter; scope of inspection; notice; promptness; exclusions
(a)(1)(1) (1)
For purposes of enforcement of this chapter, officers or employees duly designated by the Secretary, upon presenting appropriate credentials and a written notice to the owner, operator, or agent in charge, are authorized (A) to enter, at reasonable times, any factory, warehouse, or establishment in which food, drugs, devices, tobacco products, or cosmetics are manufactured, processed, packed, or held, for introduction into interstate commerce or after such introduction, or to enter any vehicle being used to transport or hold such food, drugs, devices, tobacco products, or cosmetics in interstate commerce; and (B) to inspect, at reasonable times and within reasonable limits and in a reasonable manner, such factory, warehouse, establishment, or vehicle and all pertinent equipment, finished and unfinished materials, containers, and labeling therein. In the case of any person (excluding farms and restaurants) who manufactures, processes, packs, transports, distributes, holds, or imports foods, the inspection shall extend to all records and other information described in section 350c of this title, when the standard for records inspection under paragraph (1) or (2) of section 350c(a) of this title applies, subject to the limitations established in section 350c(d) of this title. In the case of a facility (as defined in section 364 of this title) that manufactures or processes cosmetic products, the inspection shall extend to all records and other information described in sections 364a, 364b, and 364f of this title, when the standard for records inspection under such section applies. In the case of any factory, warehouse, establishment, or consulting laboratory in which prescription drugs, nonprescription drugs intended for human use, devices, or [struck: tobacco] products are manufactured, processed, packed, or held, the inspection shall extend to all things therein (including records, files, papers, processes, controls, and facilities) bearing on whether prescription drugs, nonprescription drugs intended for human use, devices, or [struck: tobacco] products which are adulterated or misbranded within the meaning of this chapter, or which may not be manufactured, introduced into interstate commerce, or sold, or offered for sale by reason of any provision of this chapter, have been or are being manufactured, processed, packed, transported, or held in any such place, or otherwise bearing on violation of this chapter. No inspection authorized by the preceding sentence or by paragraph (3) shall extend to financial data, sales data other than shipment data, pricing data, personnel data (other than data as to qualification of technical and professional personnel performing functions subject to this chapter), and research data (other than data relating to new drugs, antibiotic drugs, devices, and [struck: tobacco] products and subject to reporting and inspection under regulations lawfully issued pursuant to section 355(i) or (k) of this title, section 360i of this title, section 360j(g) of this title, or subchapter IX and data relating to other drugs, devices, or [struck: tobacco] products which in the case of a new drug would be subject to reporting or inspection under lawful regulations issued pursuant to section 355(j) of this title). A separate notice shall be given for each such inspection, but a notice shall not be required for each entry made during the period covered by the inspection. Each such inspection shall be commenced and completed with reasonable promptness.For purposes of enforcement of this chapter, officers or employees duly designated by the Secretary, upon presenting appropriate credentials and a written notice to the owner, operator, or agent in charge, are authorized (A) to enter, at reasonable times, any factory, warehouse, or establishment in which food, drugs, devices, tobacco products, [inserted: cannabinoid products, ]or cosmetics are manufactured, processed, packed, or held, for introduction into interstate commerce or after such introduction, or to enter any vehicle being used to transport or hold such food, drugs, devices, tobacco products, [inserted: cannabinoid products, ]or cosmetics in interstate commerce; and (B) to inspect, at reasonable times and within reasonable limits and in a reasonable manner, such factory, warehouse, establishment, or vehicle and all pertinent equipment, finished and unfinished materials, containers, and labeling therein. In the case of any person (excluding farms and restaurants) who manufactures, processes, packs, transports, distributes, holds, or imports foods, the inspection shall extend to all records and other information described in section 350c of this title, when the standard for records inspection under paragraph (1) or (2) of section 350c(a) of this title applies, subject to the limitations established in section 350c(d) of this title. In the case of a facility (as defined in section 364 of this title) that manufactures or processes cosmetic products, the inspection shall extend to all records and other information described in sections 364a, 364b, and 364f of this title, when the standard for records inspection under such section applies. In the case of any factory, warehouse, establishment, or consulting laboratory in which prescription drugs, nonprescription drugs intended for human use, devices, [inserted: tobacco products, ]or [inserted: cannabinoid] products are manufactured, processed, packed, or held, the inspection shall extend to all things therein (including records, files, papers, processes, controls, and facilities) bearing on whether prescription drugs, nonprescription drugs intended for human use, devices, [inserted: tobacco products, ]or [inserted: cannabinoid] products which are adulterated or misbranded within the meaning of this chapter, or which may not be manufactured, introduced into interstate commerce, or sold, or offered for sale by reason of any provision of this chapter, have been or are being manufactured, processed, packed, transported, or held in any such place, or otherwise bearing on violation of this chapter. No inspection authorized by the preceding sentence or by paragraph (3) shall extend to financial data, sales data other than shipment data, pricing data, personnel data (other than data as to qualification of technical and professional personnel performing functions subject to this chapter), and research data (other than data relating to new drugs, antibiotic drugs, devices, [inserted: tobacco products, ]and [inserted: cannabinoid] products and subject to reporting and inspection under regulations lawfully issued pursuant to section 355(i) or (k) of this title, section 360i of this title, section 360j(g) of this title, or subchapter IX and data relating to other drugs, devices, [inserted: tobacco products, ]or [inserted: cannabinoid] products which in the case of a new drug would be subject to reporting or inspection under lawful regulations issued pursuant to section 355(j) of this title). A separate notice shall be given for each such inspection, but a notice shall not be required for each entry made during the period covered by the inspection. Each such inspection shall be commenced and completed with reasonable promptness.
(a)(2)(2) (2)
The provisions of the third sentence of paragraph (1) shall not apply to—The provisions of the third sentence of paragraph (1) shall not apply to—
(a)(2)(A)(A) (A)
pharmacies which maintain establishments in conformance with any applicable local laws regulating the practice of pharmacy and medicine and which are regularly engaged in dispensing prescription drugs or devices, upon prescriptions of practitioners licensed to administer such drugs or devices to patients under the care of such practitioners in the course of their professional practice, and which do not, either through a subsidiary or otherwise, manufacture, prepare, propagate, compound, or process drugs or devices for sale other than in the regular course of their business of dispensing or selling drugs or devices at retail;pharmacies which maintain establishments in conformance with any applicable local laws regulating the practice of pharmacy and medicine and which are regularly engaged in dispensing prescription drugs or devices, upon prescriptions of practitioners licensed to administer such drugs or devices to patients under the care of such practitioners in the course of their professional practice, and which do not, either through a subsidiary or otherwise, manufacture, prepare, propagate, compound, or process drugs or devices for sale other than in the regular course of their business of dispensing or selling drugs or devices at retail;

§ 374(a)–(c)

(a)(2)(B)–(5)(E) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(a)(5)(F)(F) (F)
This paragraph clarifies the authority of the Secretary to conduct inspections of the type described in this paragraph and shall not be construed as a basis for inferring that, prior to December 29, 2022, the Secretary lacked the authority to conduct such inspections, including under this chapter or the Public Health Service Act.This paragraph clarifies the authority of the Secretary to conduct inspections of the type described in this paragraph and shall not be construed as a basis for inferring that, prior to December 29, 2022, the Secretary lacked the authority to conduct such inspections, including under this chapter or the Public Health Service Act.
(b)(b) Written report to owner; copy to Secretary(b) Written report to owner; copy to Secretary
(b)(1)(1) (1)
Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, tobacco product, or cosmetic in such establishment (A) consists in whole or in part of any filthy, putrid, or decomposed substance, or (B) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary.Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, tobacco product, [inserted: cannabinoid product, ]or cosmetic in such establishment (A) consists in whole or in part of any filthy, putrid, or decomposed substance, or (B) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary.
(b)(2)(2) (2)
In carrying out this subsection with respect to any establishment manufacturing a drug approved under subsection (c) or (j) of section 355 of this title for which a notification has been submitted in accordance with section 356c of this title is, or has been in the last 5 years, listed on the drug shortage list under section 356e of this title, or that is described in section 355(j)(11)(A) of this title, a copy of the report shall be sent promptly to the appropriate offices of the Food and Drug Administration with expertise regarding drug shortages.In carrying out this subsection with respect to any establishment manufacturing a drug approved under subsection (c) or (j) of section 355 of this title for which a notification has been submitted in accordance with section 356c of this title is, or has been in the last 5 years, listed on the drug shortage list under section 356e of this title, or that is described in section 355(j)(11)(A) of this title, a copy of the report shall be sent promptly to the appropriate offices of the Food and Drug Administration with expertise regarding drug shortages.
(c)(c) Receipt for samples taken(c) Receipt for samples taken
If the officer or employee making any such inspection of a factory, warehouse, or other establishment has obtained any sample in the course of the inspection, upon completion of the inspection and prior to leaving the premises he shall give to the owner, operator, or agent in charge a receipt describing the samples obtained.If the officer or employee making any such inspection of a factory, warehouse, or other establishment has obtained any sample in the course of the inspection, upon completion of the inspection and prior to leaving the premises he shall give to the owner, operator, or agent in charge a receipt describing the samples obtained.

Rest of § 374 unchanged

21 U.S.C. § 375 Publicity

+1 −1Shown
More for 21 U.S.C. § 375
Read § 375Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 705(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 375(b)) is amended by inserting cannabinoid products, after tobacco products,.

§ 375(a)–(b)

WhereMarkThe Code nowMarkAs the bill would leave it
§ 375. Publicity§ 375. Publicity
(a)(a) Reports(a) Reports
The Secretary shall cause to be published from time to time reports summarizing all judgments, decrees, and court orders which have been rendered under this chapter, including the nature of the charge and the disposition thereof.The Secretary shall cause to be published from time to time reports summarizing all judgments, decrees, and court orders which have been rendered under this chapter, including the nature of the charge and the disposition thereof.
(b)(b) Information regarding certain goods(b) Information regarding certain goods
The Secretary may also cause to be disseminated information regarding food, drugs, devices, tobacco products, or cosmetics in situations involving, in the opinion of the Secretary, imminent danger to health or gross deception of the consumer. Nothing in this section shall be construed to prohibit the Secretary from collecting, reporting, and illustrating the results of the investigations of the Department.The Secretary may also cause to be disseminated information regarding food, drugs, devices, tobacco products, [inserted: cannabinoid products, ]or cosmetics in situations involving, in the opinion of the Secretary, imminent danger to health or gross deception of the consumer. Nothing in this section shall be construed to prohibit the Secretary from collecting, reporting, and illustrating the results of the investigations of the Department.

21 U.S.C. § 379a Presumption of existence of jurisdiction

+1 −1Shown
More for 21 U.S.C. § 379a
Read § 379aOnly this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 709 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379a) is amended by inserting cannabinoid product, after tobacco product,.

§ 379a

WhereMarkThe Code nowMarkAs the bill would leave it
§ 379a. Presumption of existence of jurisdiction§ 379a. Presumption of existence of jurisdiction
In any action to enforce the requirements of this chapter respecting a device, tobacco product, food, drug, or cosmetic the connection with interstate commerce required for jurisdiction in such action shall be presumed to exist.In any action to enforce the requirements of this chapter respecting a device, tobacco product, [inserted: cannabinoid product, ]food, drug, or cosmetic the connection with interstate commerce required for jurisdiction in such action shall be presumed to exist.

21 U.S.C. § 381 Imports and exports

+2 −23 of 4 shown
More for 21 U.S.C. § 381
Read § 381Only this section
4 changes the bill asks for here, 3 carried out
  1. Carried out:

    by inserting cannabinoid products, after tobacco products,;

  2. Carried out:

    by striking or tobacco products each place it appears and inserting , tobacco products, or cannabinoid products; and

  3. Not carried out:

    by striking or section 905(h) and inserting , 905(h), or 1103; and

    “or section 905(h)” isn't in § 381(a) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“or section 905(h)” not found in /us/usc/t21/s381/a
  4. Carried out:

    in subsection (e), by striking tobacco product or and inserting tobacco product, cannabinoid product, or.

§ 381(a)–(c)

WhereMarkThe Code nowMarkAs the bill would leave it
§ 381. Imports and exports§ 381. Imports and exports
(a)(a) Imports; list of registered foreign establishments; samples from unregistered foreign establishments; examination and refusal of admission(a) Imports; list of registered foreign establishments; samples from unregistered foreign establishments; examination and refusal of admission
The Secretary of the Treasury shall deliver to the Secretary of Health and Human Services, upon his request, samples of food, drugs, devices, tobacco products, and cosmetics which are being imported or offered for import into the United States, giving notice thereof to the owner or consignee, who may appear before the Secretary of Health and Human Services and have the right to introduce testimony. The Secretary of Health and Human Services shall furnish to the Secretary of the Treasury a list of establishments registered pursuant to subsection (i) of section 360 or section 387e(h) of this title and shall request that if any drugs, devices, [struck: or] tobacco products manufactured, prepared, propagated, compounded, or processed in an establishment not so registered are imported or offered for import into the United States, samples of such drugs, devices, [struck: or] tobacco products be delivered to the Secretary of Health and Human Services, with notice of such delivery to the owner or consignee, who may appear before the Secretary of Health and Human Services and have the right to introduce testimony. If it appears from the examination of such samples or otherwise that (1) such article has been manufactured, processed, or packed under insanitary conditions or, in the case of a device, the methods used in, or the facilities or controls used for, the manufacture, packing, storage, or installation of the device do not conform to the requirements of section 360j(f) of this title, or (2) such article is forbidden or restricted in sale in the country in which it was produced or from which it was exported, or (3) such article is adulterated, misbranded, or in violation of section 355 of this title or the importer (as defined in section 384a of this title) is in violation of such section 384a of this title, or prohibited from introduction or delivery for introduction into interstate commerce under section 331(ll) of this title, or is a controlled substance subject to an order under section 360bbb–8d of this title, or (4) the recordkeeping requirements under section 2223 of this title (other than the requirements under subsection (f) of such section) have not been complied with regarding such article or (5) such article is being imported or offered for import in violation of section 331(cc) of this title, then any such article described in any of clauses (1) through (5) shall be refused admission, except as provided in subsection (b) of this section. If it appears from the examination of such samples or otherwise that the article is a counterfeit drug or counterfeit device, such article shall be refused admission. With respect to an article of food, if importation of such food is subject to, but not compliant with, the requirement under subsection (q) that such food be accompanied by a certification or other assurance that the food meets applicable requirements of this chapter, then such article shall be refused admission. If such article is subject to a requirement under section 364a, 379aa, or 379aa–1 of this title and if the Secretary has credible evidence or information indicating that the responsible person (as defined in section 364, 379aa, or 379aa–1 of this title) has not complied with a requirement of such section 364a, 379aa, or 379aa–1 of this title with respect to any such article, or has not allowed access to records described in such section 364a, 379aa, or 379aa–1 of this title, then such article shall be refused admission, except as provided in subsection (b) of this section. The Secretary of the Treasury shall cause the destruction of any such article refused admission unless such article is exported, under regulations prescribed by the Secretary of the Treasury, within 90 days of the date of notice of such refusal or within such additional time as may be permitted pursuant to such regulations, except that the Secretary of Health and Human Services may destroy, without the opportunity for export, any drug, device, or tobacco product refused admission under this section, if such drug, device, or tobacco product is valued at an amount that is $2,500 or less (or such higher amount as the Secretary of the Treasury may set by regulation pursuant to section 1498(a)(1) of title 19) and was not brought into compliance as described under subsection (b). The Secretary of Health and Human Services shall issue regulations providing for notice and an opportunity to appear before the Secretary of Health and Human Services and introduce testimony, as described in the first sentence of this subsection, on destruction of a drug, device, or tobacco product under the seventh sentence of this subsection. The regulations shall provide that prior to destruction, appropriate due process is available to the owner or consignee seeking to challenge the decision to destroy the drug, device, or tobacco product. Where the Secretary of Health and Human Services provides notice and an opportunity to appear and introduce testimony on the destruction of a drug, device, or tobacco product, the Secretary of Health and Human Services shall store and, as applicable, dispose of the drug, device, or tobacco product after the issuance of the notice, except that the owner and consignee shall remain liable for costs pursuant to subsection (c). Such process may be combined with the notice and opportunity to appear before the Secretary and introduce testimony, as described in the first sentence of this subsection, as long as appropriate notice is provided to the owner or consignee. Neither clause (2) nor clause (5) of the third sentence of this subsection shall be construed to prohibit the admission of narcotic drugs, the importation of which is permitted under the Controlled Substances Import and Export Act [21 U.S.C. 951 et seq.].The Secretary of the Treasury shall deliver to the Secretary of Health and Human Services, upon his request, samples of food, drugs, devices, tobacco products, [inserted: cannabinoid products, ]and cosmetics which are being imported or offered for import into the United States, giving notice thereof to the owner or consignee, who may appear before the Secretary of Health and Human Services and have the right to introduce testimony. The Secretary of Health and Human Services shall furnish to the Secretary of the Treasury a list of establishments registered pursuant to subsection (i) of section 360 or section 387e(h) of this title and shall request that if any drugs, devices, [inserted: ,] tobacco products[inserted: ,] [inserted: or cannabinoid products ]manufactured, prepared, propagated, compounded, or processed in an establishment not so registered are imported or offered for import into the United States, samples of such drugs, devices, [inserted: ,] tobacco products[inserted: ,] [inserted: or cannabinoid products ]be delivered to the Secretary of Health and Human Services, with notice of such delivery to the owner or consignee, who may appear before the Secretary of Health and Human Services and have the right to introduce testimony. If it appears from the examination of such samples or otherwise that (1) such article has been manufactured, processed, or packed under insanitary conditions or, in the case of a device, the methods used in, or the facilities or controls used for, the manufacture, packing, storage, or installation of the device do not conform to the requirements of section 360j(f) of this title, or (2) such article is forbidden or restricted in sale in the country in which it was produced or from which it was exported, or (3) such article is adulterated, misbranded, or in violation of section 355 of this title or the importer (as defined in section 384a of this title) is in violation of such section 384a of this title, or prohibited from introduction or delivery for introduction into interstate commerce under section 331(ll) of this title, or is a controlled substance subject to an order under section 360bbb–8d of this title, or (4) the recordkeeping requirements under section 2223 of this title (other than the requirements under subsection (f) of such section) have not been complied with regarding such article or (5) such article is being imported or offered for import in violation of section 331(cc) of this title, then any such article described in any of clauses (1) through (5) shall be refused admission, except as provided in subsection (b) of this section. If it appears from the examination of such samples or otherwise that the article is a counterfeit drug or counterfeit device, such article shall be refused admission. With respect to an article of food, if importation of such food is subject to, but not compliant with, the requirement under subsection (q) that such food be accompanied by a certification or other assurance that the food meets applicable requirements of this chapter, then such article shall be refused admission. If such article is subject to a requirement under section 364a, 379aa, or 379aa–1 of this title and if the Secretary has credible evidence or information indicating that the responsible person (as defined in section 364, 379aa, or 379aa–1 of this title) has not complied with a requirement of such section 364a, 379aa, or 379aa–1 of this title with respect to any such article, or has not allowed access to records described in such section 364a, 379aa, or 379aa–1 of this title, then such article shall be refused admission, except as provided in subsection (b) of this section. The Secretary of the Treasury shall cause the destruction of any such article refused admission unless such article is exported, under regulations prescribed by the Secretary of the Treasury, within 90 days of the date of notice of such refusal or within such additional time as may be permitted pursuant to such regulations, except that the Secretary of Health and Human Services may destroy, without the opportunity for export, any drug, device, or tobacco product refused admission under this section, if such drug, device, or tobacco product is valued at an amount that is $2,500 or less (or such higher amount as the Secretary of the Treasury may set by regulation pursuant to section 1498(a)(1) of title 19) and was not brought into compliance as described under subsection (b). The Secretary of Health and Human Services shall issue regulations providing for notice and an opportunity to appear before the Secretary of Health and Human Services and introduce testimony, as described in the first sentence of this subsection, on destruction of a drug, device, or tobacco product under the seventh sentence of this subsection. The regulations shall provide that prior to destruction, appropriate due process is available to the owner or consignee seeking to challenge the decision to destroy the drug, device, or tobacco product. Where the Secretary of Health and Human Services provides notice and an opportunity to appear and introduce testimony on the destruction of a drug, device, or tobacco product, the Secretary of Health and Human Services shall store and, as applicable, dispose of the drug, device, or tobacco product after the issuance of the notice, except that the owner and consignee shall remain liable for costs pursuant to subsection (c). Such process may be combined with the notice and opportunity to appear before the Secretary and introduce testimony, as described in the first sentence of this subsection, as long as appropriate notice is provided to the owner or consignee. Neither clause (2) nor clause (5) of the third sentence of this subsection shall be construed to prohibit the admission of narcotic drugs, the importation of which is permitted under the Controlled Substances Import and Export Act [21 U.S.C. 951 et seq.].
(b)(b) Disposition of refused articles(b) Disposition of refused articles
Pending decision as to the admission of an article being imported or offered for import, the Secretary of the Treasury may authorize delivery of such article to the owner or consignee upon the execution by him of a good and sufficient bond providing for the payment of such liquidated damages in the event of default as may be required pursuant to regulations of the Secretary of the Treasury. If it appears to the Secretary of Health and Human Services that (1) an article included within the provisions of clause (3) of subsection (a) of this section can, by relabeling or other action, be brought into compliance with this chapter or rendered other than a food, drug, device, or cosmetic, or (2) with respect to an article described in subsection (a) relating to the requirements of section 364a, 379aa, or 379aa–1 of this title, the responsible person (as defined in section 364, 379aa, or 379aa–1 of this title) can take action that would assure that the responsible person is in compliance with section 364a, 379aa, or 379aa–1 of this title, as the case may be, final determination as to admission of such article may be deferred and, upon filing of timely written application by the owner or consignee and the execution by him of a bond as provided in the preceding provisions of this subsection, the Secretary may, in accordance with regulations, authorize the applicant, or, with respect to clause (2), the responsible person, to perform such relabeling or other action specified in such authorization (including destruction or export of rejected articles or portions thereof, as may be specified in the Secretary’s authorization). All such relabeling or other action pursuant to such authorization shall in accordance with regulations be under the supervision of an officer or employee of the Department of Health and Human Services designated by the Secretary, or an officer or employee of the Department of the Treasury designated by the Secretary of the Treasury.Pending decision as to the admission of an article being imported or offered for import, the Secretary of the Treasury may authorize delivery of such article to the owner or consignee upon the execution by him of a good and sufficient bond providing for the payment of such liquidated damages in the event of default as may be required pursuant to regulations of the Secretary of the Treasury. If it appears to the Secretary of Health and Human Services that (1) an article included within the provisions of clause (3) of subsection (a) of this section can, by relabeling or other action, be brought into compliance with this chapter or rendered other than a food, drug, device, or cosmetic, or (2) with respect to an article described in subsection (a) relating to the requirements of section 364a, 379aa, or 379aa–1 of this title, the responsible person (as defined in section 364, 379aa, or 379aa–1 of this title) can take action that would assure that the responsible person is in compliance with section 364a, 379aa, or 379aa–1 of this title, as the case may be, final determination as to admission of such article may be deferred and, upon filing of timely written application by the owner or consignee and the execution by him of a bond as provided in the preceding provisions of this subsection, the Secretary may, in accordance with regulations, authorize the applicant, or, with respect to clause (2), the responsible person, to perform such relabeling or other action specified in such authorization (including destruction or export of rejected articles or portions thereof, as may be specified in the Secretary’s authorization). All such relabeling or other action pursuant to such authorization shall in accordance with regulations be under the supervision of an officer or employee of the Department of Health and Human Services designated by the Secretary, or an officer or employee of the Department of the Treasury designated by the Secretary of the Treasury.
(c)(c) Charges concerning refused articles(c) Charges concerning refused articles
All expenses (including travel, per diem or subsistence, and salaries of officers or employees of the United States) in connection with the destruction provided for in subsection (a) of this section and the supervision of the relabeling or other action authorized under the provisions of subsection (b) of this section, the amount of such expenses to be determined in accordance with regulations, and all expenses in connection with the storage, cartage, or labor with respect to any article refused admission under subsection (a) of this section, shall be paid by the owner or consignee and, in default of such payment, shall constitute a lien against any future importations made by such owner or consignee.All expenses (including travel, per diem or subsistence, and salaries of officers or employees of the United States) in connection with the destruction provided for in subsection (a) of this section and the supervision of the relabeling or other action authorized under the provisions of subsection (b) of this section, the amount of such expenses to be determined in accordance with regulations, and all expenses in connection with the storage, cartage, or labor with respect to any article refused admission under subsection (a) of this section, shall be paid by the owner or consignee and, in default of such payment, shall constitute a lien against any future importations made by such owner or consignee.

§ 381(d)–(e)

(d) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(d)(4)(4) (4)
The importation into the United States of blood, blood components, source plasma, or source leukocytes or of a component, accessory, or part thereof is not permitted pursuant to paragraph (3) unless the importation complies with section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] or the Secretary permits the importation under appropriate circumstances and conditions, as determined by the Secretary. The importation of tissue or a component or part of tissue is not permitted pursuant to paragraph (3) unless the importation complies with section 361 of the Public Health Service Act [42 U.S.C. 264].The importation into the United States of blood, blood components, source plasma, or source leukocytes or of a component, accessory, or part thereof is not permitted pursuant to paragraph (3) unless the importation complies with section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] or the Secretary permits the importation under appropriate circumstances and conditions, as determined by the Secretary. The importation of tissue or a component or part of tissue is not permitted pursuant to paragraph (3) unless the importation complies with section 361 of the Public Health Service Act [42 U.S.C. 264].
(e)(e) Exports(e) Exports
(e)(1)(1) (1)
A food, drug, device, tobacco product or cosmetic intended for export shall not be deemed to be adulterated or misbranded under this chapter, and a tobacco product intended for export shall not be deemed to be in violation of section 387f(e), 387g, 387k, or 387t(a) of this title, if it—A food, drug, device, tobacco product[inserted: ,] [inserted: cannabinoid product, ]or cosmetic intended for export shall not be deemed to be adulterated or misbranded under this chapter, and a tobacco product intended for export shall not be deemed to be in violation of section 387f(e), 387g, 387k, or 387t(a) of this title, if it—
(e)(1)(A)(A) (A)
accords to the specifications of the foreign purchaser,accords to the specifications of the foreign purchaser,
(e)(1)(B)(B) (B)
is not in conflict with the laws of the country to which it is intended for export,is not in conflict with the laws of the country to which it is intended for export,

Rest of § 381 unchanged

23 U.S.C. § 409 Renumbered § 407]

+74 −1Shown
More for 23 U.S.C. § 409
Read § 409Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Chapter 4 of title 23, United States Code, is amended by inserting after section 408 the following:409. State cannabis-impaired driving prevention grant program (a) Definitions.— In this section: (1) Cannabis.— The term cannabis has the meaning given the term in paragraph (tt) of section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321). (2) Grant program.— The term grant program means the grant program established under subsection (b). (3) THC.— The term THC means tetrahydrocannabinol (as defined in paragraph (vv) of section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321)). (b) Establishment.— Not later than 1 year after the date of enactment of the Cannabinoid Safety and Regulation Act, the Secretary, acting through the Administrator of the National Highway Traffic Safety Administration, shall establish a program to provide grants to States, in accordance with subsection (c), to implement programs to prevent impaired driving due to cannabis use. (c) Eligibility.— The Secretary may provide a grant under this section to any State that— (1) describes how the State will use the grant funds in accordance with a highway safety program under section 402, including how the State will implement the best practices developed by the Secretary under section 303(a)(1) of the Cannabinoid Safety and Regulation Act; and (2) agrees to provide data and information, as determined by the Secretary, to assist with the evaluation of the effectiveness of the eligible activities described in subsection (d). (d) Use of funds.— A State may use a grant awarded under this section for the following activities: (1) Enforcement activities, including— (A) to train public safety personnel to detect impaired driving due to the use of cannabis or a combination of cannabis and another substance; (B) to increase the capacity of impaired driving toxicology testing laboratories in the State to support impaired driving investigations, including to purchase equipment, hire staff, provide training, and improve procedures, including to improve toxicology testing standards to be consistent with the standards contained in the document of the National Safety Council entitled Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities–2021 Update (or a successor document); (C) to train for and implement impaired driving assessment programs or other tools designed to increase the probability of identifying the recidivism risk of an individual convicted of driving under the influence of cannabis, or a combination of cannabis and another substance, and to determine the most effective mental health or substance abuse treatment or sanction that will reduce that risk; (D) to develop and implement high-visibility enforcement efforts relating to cannabis-impaired driving; and (E) for court support of high-visibility enforcement efforts, to train and educate criminal justice professionals (including law enforcement personnel, prosecutors, judges, and probation officers) to assist those professionals in— (i) handling cannabis-impaired driving cases; (ii) hiring traffic safety resource prosecutors; (iii) hiring judicial outreach liaisons; and (iv) establishing driving while intoxicated courts. (2) Data collection activities, including— (A) to collect data relating to the use of cannabis, drugs, or multiple substances by drivers, including the prevalence of the use of those substances among drivers arrested for impaired driving; and (B) to increase drug testing and reporting for all fatal crashes and serious injuries to better understand the scope of cannabis-impaired driving, or a combination of cannabis and another substance. (3) Education activities, including— (A) to develop and carry out educational campaigns to better educate the public about the harms associated with cannabis-impaired driving, including impaired driving associated with the use of cannabis and another substance; and (B) to participate in national campaigns organized by the Secretary under section 303(a)(2) of the Cannabinoid Safety and Regulation Act. (e) Prohibition.— The Secretary may prohibit the use of grant funds for an activity described in subsection (d) if the Secretary determines that the activity is ineffective at preventing cannabis-impaired driving after conducting an evaluation required under section 303(b) of the Cannabinoid Safety and Regulation Act. (f) Grant amounts.— (1) In general.— The allocation of grant funds to a State under this section for a fiscal year shall be in proportion to the apportionment of funds a State receives under section 402(c)(2). (2) Requirement.— Not less than 10 percent of the funds allocated to a State under this section shall be used to carry out activities described in subsection (d)(1)(B). (g) Federal share.— (1) In general.— For the first 3 fiscal years after the date on which the grant program is established under subsection (b), and each fiscal year thereafter for a State that meets the condition described in paragraph (2)(B) during that fiscal year, the Federal share of the costs of activities carried out with a grant awarded under the grant program shall be 80 percent in any fiscal year in which the State is awarded a grant. (2) Decreased Federal share.— (A) In general.— For any State that does not meet the condition described in subparagraph (B), the Federal share of the costs of activities carried out with a grant awarded under the grant program shall be— (i) 70 percent in the fourth fiscal year after the date on which the grant program is established under subsection (b); (ii) 60 percent in the fifth fiscal year after that date; and (iii) 50 percent in the sixth fiscal year after that date and each fiscal year thereafter. (B) Condition.— The condition referred to in paragraph (1) and subparagraph (A) is that the State shall implement an open container law relating to cannabis products. (h) Funding.— In addition to amounts otherwise available, there is appropriated, out of any money in the Treasury not otherwise appropriated, $40,000,000 for each of fiscal years 2026 through 2030 to carry out this section..

§ 409(a)–(h)

WhereMarkThe Code nowMarkAs the bill would leave it
[§ 409. [struck: Renumbered] [struck: §] [struck: 407]][§ 409. [inserted: State] [inserted: cannabis-impaired] [inserted: driving prevention grant program]
(a)(a) [inserted: Definitions.—]
[inserted: In this section:]
(a)(1)(1) [inserted: Cannabis.—]
[inserted: The term “cannabis” has the meaning given the term in paragraph (tt) of section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321).]
(a)(2)(2) [inserted: Grant program.—]
[inserted: The term “grant program” means the grant program established under subsection (b).]
(a)(3)(3) [inserted: THC.—]
[inserted: The term “THC” means tetrahydrocannabinol (as defined in paragraph (vv) of section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321)).]
(b)(b) [inserted: Establishment.—]
[inserted: Not later than 1 year after the date of enactment of the Cannabinoid Safety and Regulation Act, the Secretary, acting through the Administrator of the National Highway Traffic Safety Administration, shall establish a program to provide grants to States, in accordance with subsection (c), to implement programs to prevent impaired driving due to cannabis use.]
(c)(c) [inserted: Eligibility.—]
[inserted: The Secretary may provide a grant under this section to any State that—]
(c)(1)(1) [inserted: ]
[inserted: describes how the State will use the grant funds in accordance with a highway safety program under section 402, including how the State will implement the best practices developed by the Secretary under section 303(a)(1) of the Cannabinoid Safety and Regulation Act; and]
(c)(2)(2) [inserted: ]
[inserted: agrees to provide data and information, as determined by the Secretary, to assist with the evaluation of the effectiveness of the eligible activities described in subsection (d).]
(d)(d) [inserted: Use of funds.—]
[inserted: A State may use a grant awarded under this section for the following activities:]
(d)(1)(1) [inserted: ]
[inserted: Enforcement activities, including—]
(d)(1)(A)(A) [inserted: ]
[inserted: to train public safety personnel to detect impaired driving due to the use of cannabis or a combination of cannabis and another substance;]
(d)(1)(B)(B) [inserted: ]
[inserted: to increase the capacity of impaired driving toxicology testing laboratories in the State to support impaired driving investigations, including to purchase equipment, hire staff, provide training, and improve procedures, including to improve toxicology testing standards to be consistent with the standards contained in the document of the National Safety Council entitled “Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities–2021 Update” (or a successor document);]
(d)(1)(C)(C) [inserted: ]
[inserted: to train for and implement impaired driving assessment programs or other tools designed to increase the probability of identifying the recidivism risk of an individual convicted of driving under the influence of cannabis, or a combination of cannabis and another substance, and to determine the most effective mental health or substance abuse treatment or sanction that will reduce that risk;]
(d)(1)(D)(D) [inserted: ]
[inserted: to develop and implement high-visibility enforcement efforts relating to cannabis-impaired driving; and]
(d)(1)(E)(E) [inserted: ]
[inserted: for court support of high-visibility enforcement efforts, to train and educate criminal justice professionals (including law enforcement personnel, prosecutors, judges, and probation officers) to assist those professionals in—]
(d)(1)(E)(i)(i) [inserted: ]
[inserted: handling cannabis-impaired driving cases;]
(d)(1)(E)(ii)(ii) [inserted: ]
[inserted: hiring traffic safety resource prosecutors;]
(d)(1)(E)(iii)(iii) [inserted: ]
[inserted: hiring judicial outreach liaisons; and]
(d)(1)(E)(iv)(iv) [inserted: ]
[inserted: establishing driving while intoxicated courts.]
(d)(2)(2) [inserted: ]
[inserted: Data collection activities, including—]
(d)(2)(A)(A) [inserted: ]
[inserted: to collect data relating to the use of cannabis, drugs, or multiple substances by drivers, including the prevalence of the use of those substances among drivers arrested for impaired driving; and]
(d)(2)(B)(B) [inserted: ]
[inserted: to increase drug testing and reporting for all fatal crashes and serious injuries to better understand the scope of cannabis-impaired driving, or a combination of cannabis and another substance.]
(d)(3)(3) [inserted: ]
[inserted: Education activities, including—]
(d)(3)(A)(A) [inserted: ]
[inserted: to develop and carry out educational campaigns to better educate the public about the harms associated with cannabis-impaired driving, including impaired driving associated with the use of cannabis and another substance; and]
(d)(3)(B)(B) [inserted: ]
[inserted: to participate in national campaigns organized by the Secretary under section 303(a)(2) of the Cannabinoid Safety and Regulation Act.]
(e)(e) [inserted: Prohibition.—]
[inserted: The Secretary may prohibit the use of grant funds for an activity described in subsection (d) if the Secretary determines that the activity is ineffective at preventing cannabis-impaired driving after conducting an evaluation required under section 303(b) of the Cannabinoid Safety and Regulation Act.]
(f)(f) [inserted: Grant amounts.—]
(f)(1)(1) [inserted: In general.—]
[inserted: The allocation of grant funds to a State under this section for a fiscal year shall be in proportion to the apportionment of funds a State receives under section 402(c)(2).]
(f)(2)(2) [inserted: Requirement.—]
[inserted: Not less than 10 percent of the funds allocated to a State under this section shall be used to carry out activities described in subsection (d)(1)(B).]
(g)(g) [inserted: Federal share.—]
(g)(1)(1) [inserted: In general.—]
[inserted: For the first 3 fiscal years after the date on which the grant program is established under subsection (b), and each fiscal year thereafter for a State that meets the condition described in paragraph (2)(B) during that fiscal year, the Federal share of the costs of activities carried out with a grant awarded under the grant program shall be 80 percent in any fiscal year in which the State is awarded a grant.]
(g)(2)(2) [inserted: Decreased Federal share.—]
(g)(2)(A)(A) [inserted: In general.—]
[inserted: For any State that does not meet the condition described in subparagraph (B), the Federal share of the costs of activities carried out with a grant awarded under the grant program shall be—]
(g)(2)(A)(i)(i) [inserted: ]
[inserted: 70 percent in the fourth fiscal year after the date on which the grant program is established under subsection (b);]
(g)(2)(A)(ii)(ii) [inserted: ]
[inserted: 60 percent in the fifth fiscal year after that date; and]
(g)(2)(A)(iii)(iii) [inserted: ]
[inserted: 50 percent in the sixth fiscal year after that date and each fiscal year thereafter.]
(g)(2)(B)(B) [inserted: Condition.—]
[inserted: The condition referred to in paragraph (1) and subparagraph (A) is that the State shall implement an open container law relating to cannabis products.]
(h)(h) [inserted: Funding.—]
[inserted: In addition to amounts otherwise available, there is appropriated, out of any money in the Treasury not otherwise appropriated, $40,000,000 for each of fiscal years 2026 through 2030 to carry out this section.]

42 U.S.C. § 280b–1 Preventing overdoses of controlled substances

+6 −45 of 6 shown
More for 42 U.S.C. § 280b–1
Read § 280b–1Only this section
6 changes the bill asks for here, 5 carried out
  1. Carried out:

    in the section heading, by inserting and adverse health effects of cannabis use after substances;

  2. Carried out:

    in subparagraph (C) by inserting and adverse health effects of cannabis use before the period; and

  3. Carried out:

    in subparagraph (D) by inserting , cannabis, and polysubstance use before the period; and

  4. Carried out:

    in paragraph (4), by inserting and collect data to better understand the use and health effects of cannabis, stimulants, and polysubstances, and after conduct studies and evaluations;

  5. Not carried out:

    in subsection (e), by striking $496,000,000 for each of fiscal years 2019 through 2023 and inserting $596,000,000 for each of fiscal years 2026 through 2030; and

    “$496,000,000 for each of fiscal years 2019 through 2023” isn't in § 280b–1(e) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“$496,000,000 for each of fiscal years 2019 through 2023” not found in /us/usc/t42/s280b–1/e
  6. Carried out:

    by adding at the end the following:(f) Additional funding.— In addition to amounts otherwise available, there is appropriated, out of any funds in the Treasury not otherwise appropriated, $100,000,000 for each of fiscal years 2026 through 2030 to carry out this section..

§ 280b–1(a)

WhereMarkThe Code nowMarkAs the bill would leave it
§ 280b–1. Preventing overdoses of controlled substances§ 280b–1. Preventing overdoses of controlled substances[inserted: and adverse health effects of cannabis use]
(a)(a) Evidence-based prevention grants(a) Evidence-based prevention grants
(a)(1)(1) In general(1) In general
The Director of the Centers for Disease Control and Prevention may—The Director of the Centers for Disease Control and Prevention may—

§ 280b–1(a)–(b)

(a)(1)(A)–(2)(A) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(a)(2)(B)(B) (B)
Promoting community or health system interventions.Promoting community or health system interventions.
(a)(2)(C)(C) (C)
Evaluating interventions to prevent controlled substance overdoses and associated risks.Evaluating interventions to prevent controlled substance overdoses and associated risks[inserted: and adverse health effects of cannabis use].
(a)(2)(D)(D) (D)
Implementing projects to advance an innovative prevention approach with respect to new and emerging public health crises and opportunities to address such crises, such as enhancing public education and awareness on the risks associated with substances causing overdose.Implementing projects to advance an innovative prevention approach with respect to new and emerging public health crises and opportunities to address such crises, such as enhancing public education and awareness on the risks associated with substances causing overdose[inserted: , cannabis, and polysubstance use].
(a)(3)(3) Additional grants(3) Additional grants
The Director may award grants to States, localities, and Indian Tribes for the following purposes:The Director may award grants to States, localities, and Indian Tribes for the following purposes:
(a)(3)(A)(A) (A)
To carry out innovative projects for grantees to detect, identify, and rapidly respond to controlled substance misuse, abuse, and overdoses, and associated risk factors, including changes in patterns of such controlled substance use. Such projects may include the use of innovative, evidence-based strategies for detecting such patterns, such as wastewater surveillance, if proven to support actionable prevention strategies, in a manner consistent with applicable Federal and State privacy laws.To carry out innovative projects for grantees to detect, identify, and rapidly respond to controlled substance misuse, abuse, and overdoses, and associated risk factors, including changes in patterns of such controlled substance use. Such projects may include the use of innovative, evidence-based strategies for detecting such patterns, such as wastewater surveillance, if proven to support actionable prevention strategies, in a manner consistent with applicable Federal and State privacy laws.
(a)(3)(B)(B) (B)
For any other evidence-based activity for preventing controlled substance misuse, abuse, and overdoses as the Director determines appropriate.For any other evidence-based activity for preventing controlled substance misuse, abuse, and overdoses as the Director determines appropriate.
(a)(4)(4) Research(4) Research
The Director, in coordination with the Assistant Secretary for Mental Health and Substance Use and the National Mental Health and Substance Use Policy Laboratory established under section 290aa–0 of this title, as appropriate and applicable, may conduct studies and evaluations to address substance use disorders, including preventing substance use disorders or other related topics the Director determines appropriate.The Director, in coordination with the Assistant Secretary for Mental Health and Substance Use and the National Mental Health and Substance Use Policy Laboratory established under section 290aa–0 of this title, as appropriate and applicable, may conduct studies and evaluations [inserted: and collect data ]to [inserted: better understand the use and health effects of cannabis, stimulants, and polysubstances, and to ]address substance use disorders, including preventing substance use disorders or other related topics the Director determines appropriate.
(b)(b) Enhanced controlled substance overdose data collection, analysis, and dissemination grants(b) Enhanced controlled substance overdose data collection, analysis, and dissemination grants
(b)(1)(1) In general(1) In general
The Director of the Centers for Disease Control and Prevention may—The Director of the Centers for Disease Control and Prevention may—

§ 280b–1(d)–(f)

(b)(1)(A)–(d)(1) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(d)(2)(2) Indian tribe(2) Indian tribe
The term “Indian tribe” has the meaning given that term in section 5304 of title 25.The term “Indian tribe” has the meaning given that term in section 5304 of title 25.
(e)(e) Authorization of appropriations(e) Authorization of appropriations
For purposes of carrying out this section, section 280g–3 of this title, and section 290bb–25g of this title, there is authorized to be appropriated $505,579,000 for each of fiscal years 2026 through 2030.For purposes of carrying out this section, section 280g–3 of this title, and section 290bb–25g of this title, there is authorized to be appropriated $505,579,000 for each of fiscal years 2026 through 2030.
(f)(f) [inserted: Additional funding.—]
[inserted: In addition to amounts otherwise available, there is appropriated, out of any funds in the Treasury not otherwise appropriated, $100,000,000 for each of fiscal years 2026 through 2030 to carry out this section.]

Step through the changes